Pancreatic ductal adenocarcinoma (PDAC) has a dismal prognosis, with a median survival
time of 10-12 months. Clinically, these poor outcomes are attributed to several factors …

Pancreatic ductal adenocarcinoma (PDAC) is one of the leading causes of cancer-related
deaths. PDAC remains one of the most difficult-to-treat cancers, owing to its unique …

Immunotherapy has gained increasing focus in treating pancreatic ductal adenocarcinoma
(PDAC), since conventional therapies like chemotherapy could not provide satisfactory …

The adoptive transfer of T cells redirected to tumor-associated antigens via transgenic
expression of chimeric antigen receptors (CARs) has produced tumor responses, even in …

Pancreatic cancer (PC) is the most aggressive type of common cancers, and in 2014, nearly
40000 patients died from the disease in the United States. Pancreatic ductal …

Pancreatic ductal adenocarcinoma (PDAC) is one of the most lethal human malignancies
with a 5-year survival rate of 8%. Dense, fibrotic stroma associated with pancreatic tumors is …

Pancreatic ductal adenocarcinoma (PDAC) is a malignancy with one of the worst prognoses
worldwide and has an overall 5-year survival rate of only 9%. Although chemotherapy is the …

Pancreatic cancer remains one of the most lethal cancers with few treatment options.
Immune-based strategies to treat pancreatic cancer, such as immune checkpoint inhibitors …

Despite tremendous progress achieved in immunotherapy, many critical challenges in
treating pancreatic ductal adenocarcinoma (PDAC) persist. Considering the poor …

Background & Aims Little is known about mechanisms of perineural invasion (PNI) by
pancreatic ductal adenocarcinomas (PDAs) or other tumors. Annexin A2 (ANXA2) regulates …